Chardan analyst Keay Nakae lowered the firm’s price target on Sonnet BioTherapeutics to $12 from $14 and keeps a Buy rating on the shares following the fiscal Q3 report. The reduced target reflects a higher projected future share count as modeled capital raises are expected to be more dilutive due to the decline in shares, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SONN:
- Sonnet BioTherapeutics announces FDA acceptance of IND for SB221 trial
- Sonnet BioTherapeutics reports Q3 EPS (13c) vs. ($1.82) last year
- Sonnet BioTherapeutics files to sell 5.15M shares of common stock for holders
- Sonnet BioTherapeutics announces $2.25M registered direct offering
- Sonnet BioTherapeutics to present at Cytokine-Based Drug Development Summit
